Equillium (EQ) Convertible Debt (2017 - 2018)
Equillium (EQ) posted quarterly Convertible Debt of $10.3 million for Q3 2018, up 47.56% quarter-over-quarter from $7.0 million in Q4 2017.
Powered by 
Analysis
Equillium (EQ) Convertible Debt (2017 - 2018) Analysis & Trends
Equillium (EQ) has reported Convertible Debt for 2 consecutive years, with $10.3 million the latest figure, recorded in Q3 2018.
- In Q3 2018, Convertible Debt changed N/A year-over-year to $10.3 million; the TTM figure through Sep 2018 stood at $10.3 million (changed N/A YoY), while the FY2017 annual figure was $7.0 million, changed N/A from the prior year.
- Convertible Debt climbed to $10.3 million in Q3 2018 per EQ's latest filing, from $7.0 million in the prior quarter.
- Across five years, Convertible Debt topped out at $10.3 million in Q3 2018 and bottomed at $7.0 million in Q4 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Equillium | 249.33 Mn | 249.33 Mn | - |